三维空间~(125)I粒子组织间植入术治疗前列腺癌的疗效观察

目的探讨^125I粒子组织间植入治疗前列腺癌的临床价值。方法在经直肠B超引导定位下，经会阴部穿刺前列腺^125I粒子植入治疗前列腺癌5例，其中3例合并骨转移。结果5例手术均顺利，平均植入^125I粒子40例，平均手术时间75min，平均住院时间6d。术后随访3-11个月，平均5个月，完全反应3例，部分反应1例，病情恶化1例。PSA无进展生存率为80％（4／5），无严重并发症发生。结论^125粒子组织间植入治疗前列腺癌是一种安全、创伤小、并发症低且疗效肯定的微创方法。

Permanent 125I prostate brachytherapy for prostate cancer

Objective] To study the clinical significance of peranent ^125I prostate brachytherapy for prostate cancer. Methods] A total of 5 patinets of prostate cancer underwent 3-dimensional eonformal braehytherapy with transperineal ultrasound-gnide ^125I seeds prostate implantation, of then 3 patinets with bone metastases. Results] The mean number of ^125I seeds implantated was 40. The mean operating time was 75 mins, and mean hospitalization was 6 d. All patients were followed up for 3 to 11 months with a mean of 5 months.3 eases had completed reaction; 1, partieal reaction; 1, developed progressive disease. PSA progression-free survival rate was 80%. No severe complication occurred. Conclusions] Braehytherapy with ^125I seeds implantation guided by transreetal ultrasound is a safe, minimally invasive and effective treatment with low morbidity of complication for prostate cancer patients.